XLs proved very efficient in describing metastatic inter-lesion heterogeneous patterns correlating with patient lesion-specific response and defined a mechanism of resistance to anti-HER2 therapy in CRC [37]. The gene discussed is ERBB2; the disease is colorectal carcinoma.